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Abstract. Intracapsular and well‑defined adenocarcinomas of
the prostate are often surrounded by tissue areas that harbor
molecular aberrations, including those of genetic, epigenetic
and biochemical nature. This is known as field cancerization,
or a field effect and denotes a state of pre‑malignancy. Such
alterations in histologically normal tumor‑adjacent prostatic
tissues have been recognized as clinically important and
are potentially exploitable as biomarkers of disease and/or
targets for preventative/therapeutic intervention. The authors
have previously identified and validated two protein markers
of field cancerization: The expressional upregulation of the
transcription factor early growth response 1 (EGR‑1) and the
lipogenic enzyme fatty acid synthase (FASN). However, the
molecular etiology of prostate field cancerization, including
EGR‑1 and FASN upregulation, remains largely unknown.
It was thus hypothesized that extracellular vesicles, notably
exosomes, released by tumor lesions may induce molecular
alterations in the surrounding tissues, resulting in field
cancerization, priming the tissue, and ultimately promoting
multifocal tumorigenesis, which is often observed in prostate
cancer. Towards testing this hypothesis, the current study,
to the best of our knowledge, for the first time, presents
correlative protein expression data, generated in disease‑free,
tumor‑adjacent and cancerous human prostate tissues by quantitative immunofluorescence, between the exosomal marker
CD9, and EGR‑1 and FASN. Despite the pilot character of
the present study, and the static nature and heterogeneity of
human tissues, the data suggest that CD9 expression itself is
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part of a field effect. In support of this hypothesis, the results
suggest a possible contribution of exosomes to the induction
of field cancerization in the prostate, particularly for EGR‑1.
These findings were corroborated in established cell models
of cancerous (LNCaP) and non‑cancerous (RWPE‑1) human
prostate epithelial cells. The findings of this study warrant
further investigation into the functional interface between
exosomes and field cancerization, as a detailed understanding
of this characterization may lead to the development of clinical
applications related to diagnosis and/or prognosis and targeted
intervention to prevent progression from pre‑malignancy to
cancer.
Introduction
Since the otolaryngologist Danely Slaughter introduced the
concept of field cancerization in 1953 in stratified squamous
epithelia of the oral mucosa of patients suffering from oral
diseases (1), the definition of this term, also known as the
field effect, field defect, or field carcinogenesis, has changed
mainly due to the rapid development of analytical techniques
in molecular biology and genetics developed over the past
decades. First, the original intent was to describe the occurrence of cancerous cells in histologically normal tissues at
some distances from the primary lesions, and to explain the
multifocality of solid tumors, particularly in the case of oral
cancers, including squamous cell carcinomas (1,2). These
cells are by definition clinically detectable. By contrast, the
current definition of field cancerization applies to structurally and phenotypically intact cells residing in histologically
normal tissues outside the confinement of the primary tumor.
These cells do not typically distinguish themselves from their
surrounding and thus remain clinically hidden. The latter
points to the second major change of the term ‘field cancerization’, i.e., the shift in focus on the molecular characterization
of affected cells and tissues, as opposed to their phenotypical
appearance (3). Consequently, cells that are part of ‘field
cancerized’ tissues are considered to be molecularly altered in
the absence of other visually obvious changes. Furthermore,
the nature of these molecular alterations is typically indicative
of a positively ‘primed’ or ‘committed’ status with respect to
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cell proliferation, growth, migration and/or survival, essentially delineating the affected cells as pre‑malignant (4‑6).
The authors have continuously contributed to the molecular
characterization of field cancerization in prostate tissues by
describing both genetic and biochemical deviations from
normalcy (7‑13). This has included the observation of telomere
attrition (9), as well as the upregulation of protein expression,
including the key transcription factor early growth response 1
(EGR‑1) and the anabolic enzyme fatty acid synthase
(FASN) (7,11).
Although the importance of field cancerization in representing a type of pre‑malignancy in tissues that are prone to
tumorigenesis has been recognized and acknowledged, the
molecular and cellular mechanisms underpinning its etiology,
while often discussed, remain largely unknown (4‑6). This is
also true for field cancerization in prostatic tissues and stands
in contrast to the growing list of molecular and cellular markers
describing it (13,14). A recent focus in urological research has
been the functional role of extracellular vesicles released by
virtually all types of cells in the prostate as part of inter‑cell
and inter‑organ compartment communication (15,16). These
extracellular vesicles include exosomes that have been characterized to be in the range of 30‑150 nanometers in diameter.
The importance of exosomal function in normal prostate
physiology has been well recognized and is primarily due to
their biologically active ‘cargo’ that includes multiple types of
RNAs, lipids and proteins (17‑20). Conceptually, the biochemical composition of exosomes reflects the current physiology of
the cell of origin. It is thus not inconceivable to assume that a
specific physiological signature can be conveyed or transferred
to recipient cells. This line of thought has led to the hypothesis
of a potential role of exosome release and action in the etiology
of field cancerization. The authors have thus begun to test
this hypothesis by assessing a potential correlation in protein
expression between the exosomal marker and tetraspanin,
CD9, and the afore‑mentioned field cancerization markers,
EGR‑1 and FASN, in human prostate tissues. Cultured cell
models of prostate cancer were also used to corroborate these
findings. The results indicate a possible association between
exosomes and the expression of EGR‑1 and potentially, that of
FASN in prostate tissues affected by field cancerization. This
novel insight into pathways underlying prostate field effect
may lead to the development of targeted intervention strategies
preventing progression from pre‑malignancy to cancer.
Materials and methods
Tissues and cells. Tissue microarrays (TMAs) were purchased
from US Biomax, Inc. (https://www.biomax.us/). No human
tissues from other sources, other than commercially available
TMAs, were used in the present study. The use of any human
tissues, including commercially available TMAs, is covered
by the Chapman University Institutional Review Board (IRB)
study #1415H024. For the present study, the formalin‑fixed
and paraffin‑embedded (FFPE) TMA BC 19021a was
used, featuring 5‑µm‑thick cancerous, tumor‑adjacent and
disease‑free (normal) human prostate tissue cores of 1.5 mm in
diameter. Experiments with human tissues was approved by the
Institutional Review Board of Chapman University. The tissue
cohort analyzed in this study consisted of 8 adenocarcinomas,

8 tumor‑adjacent tissues, and 6 disease‑free tissues. These
were selected for inclusion to represent variation in age and
tumor stage and based on immunofluorescence quality. The
matching status of the tumor‑adjacent tissues with the featured
tumors is unknown. Also unknown was the distance from
the tumor margin at which adjacent tissues were resected.
However, a common practice in our own research is resection
at a distance of approximately 1 cm from the visible tumor
margin (7‑11,21). The definition of the term ‘disease‑free’
refers to prostate specimens from autopsy cases from
individuals who died due to conditions unrelated to cancer.
The mean age of all cases utilized was 54.7 years with a range
of 21‑80 years. The cancer specimens featured Gleason scores
from 4 to 10 and pathological tumor node metastasis (TNM)
stages (according to the American Joint Committee on Cancer;
https://cancerstaging.org/Pages/default.aspx) from T2aN0M0
to T2N1M1b (Table I).
Non‑cancerous RWPE‑1 and cancerous LNCaP human
prostate epithelial cells were purchased from the American
Type Culture Collection (ATCC) and cultured in serum‑free
keratinocyte basal medium containing 4,500 mg/l glucose,
0.05 mg/ml bovine pituitary extract and 5 ng/ml recombinant
epidermal growth factor (EGF) (for RWPE‑1), or in RPMI‑1640
medium supplemented with 10% heat‑inactivated (56˚C, 1 h)
fetal bovine serum (FBS) and 100 U/ml penicillin/streptomycin (for LNCaP). Cells were maintained at 37˚C in a
humidified 5% CO2 atmosphere. Trypsin‑EDTA at 0.25% was
used to detach the cells for splitting and re‑culturing.
Immunofluorescence. Immunofluorescence was performed
as described in previous studies by the authors on prostate
field cancerization (7,10,11). In order to query the same tissue
areas for the three protein markers under investigation (CD9,
EGR‑1 and FASN), consecutive sections, each 5 µm apart
from each other were used (Fig. 1). TMAs were subjected to
deparaffinization with xylene and rehydrated with decreasing
concentrations of ethanol. Antigen retrieval was performed in
boiling 10 mM Tris, 1 mM EDTA, 0.05% Tween‑20, pH 9.0
(by HCl) for 10 min, washed briefly in tap water, followed by
gentle agitation in Tris buffered saline (TBS; 50 mM Tris,
150 mM NaCl, pH 7.6 by HCl) containing 0.025% Triton
X‑100 (TBST). Tissues were blocked in 10% normal goat
serum (sc‑2040, Santa Cruz Biotechnology) in TBS containing
1% bovine serum antigen (BSA) for 2 h at room temperature,
then incubated with primary antibodies in TBS containing
1% BSA at 4˚C overnight. These were all mouse monoclonal antibodies from Abcam used at 3 µg/ml: Anti‑CD9
(ab2215), anti‑EGR‑1 (ab55160) and anti‑FASN (ab218306).
The control antibody to ensure target specificity at the same
concentration was normal mouse IgG (GC270, Millipore).
The corresponding secondary antibody, used at a dilution of
1:750, was Alexa Fluor 594‑conjugated goat anti‑mouse IgG
(A11005, Life Technologies; Thermo Fisher Scientific; excitation at 590 nm, emission at 618 nm). Nuclear counterstaining
was performed with diamidino‑2‑phenylindole (DAPI) in TBS
for 2 min. Fluorescence was preserved using Fluoroshield
solution (Sigma) under coverslips sealed with nail polish. Cells
were cultured and prepared for qualitative immunofluorescence concomitantly (on the same slide) on Millicell EZ slides
(Millipore) to ensure equal experimental and thus comparative
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Table I. Demographics and clinical parameters of prostate tissues, and the no. of images analyzed.
No. of images

Prostate tissues

Age, years

TNMa

Gleason score

--------------------------------------------------------------------------------

CD9

EGR‑1

Disease‑free						
1
21			
6
6
2
21			
5
5
3
25
		
6
10
Not applicable
4
25			
6
9
5
27			
6
8
6
27			
6
10
Total				
35
48
Adjacent						
1
40			
7
8
2
76			
6
7
3
73			
7
8
4
73
8
8
Not available		
5
62			
6
9
6
62			
6
6
7
72			
7
7
8
80			
6
7
Total				
53
60
Tumor						
1
76
T2aN0M0
4 (2+2)
6
6
2
76
T2aN0M0
4 (2+2)
6
6
3
72
T2N0M0
6 (3+3)
7
8
4
72
T2N0M0
6 (3+3)
6
7
5
40
T2N1M1b
9 (5+4)
6
6
6
40
T2N1M1b
9 (5+4)
7
5
7
72
T2N0M1
10 (5+5)
6
6
8
72
T2N0M1
10 (5+5)
5
7
Total				
49
51

FASN
3
5
6
4
5
5
28
5
3
7
7
5
6
7
4
44
5
2
4
5
6
5
5
5
37

A total of 8 adenocarcinomas (tumor), 8 tumor adjacent tissues (adjacent), and 6 disease‑free tissues were analyzed. In total, 336 images were
queried (numbers for each case and marker are indicated). aTumor nodes netastasis (TNM) pathological stage was assigned using criteria
published by the American Joint Committee on Cancer (https://cancerstaging.org/Pages/default.aspx). EGR‑1, early growth response 1; FASN,
fatty acid synthase.

treatment. The cells were fixed in 4% formaldehyde followed
by 3 washes in TBS and stained as for the tissues above.
Fluorescence for both cells and tissues was detected
using an A1R Nikon confocal microscope available at the
Chapman University School of Pharmacy Microscopy Core
Facility. For the tissues, fluorescence was quantified using the
NIS‑Elements AR 4.30.02/64bit software to analyze acquired
digital images. Consistent with previous studies by the
authors (7,10,11), the fluorescence signal acquisition mode was
applied to 2‑10 images per tissue sample. Great care was taken
in choosing tissue areas with as equal as possible numbers of
DAPI‑stained nuclei from epithelial compartments to account
for equal number of cells analyzed. In addition, identical areas
on the consecutive sections were imaged for the three specific
protein markers (CD9, EGR‑1 and FASN) to allow the reported

correlation analyses. For all specific markers, the acquisition
setting was kept identical for all images taken to ensure the
validity of intra‑ and inter‑tissue comparisons. The number
of images amenable to quantitative fluorescence analysis
per individual tissue and protein marker under investigation
is indicated in Table I. In total, 336 images with associated
quantitative immunofluorescence data were available for the
present analysis.
Isolation of exosomes. Exosomes were isolated from cancerous
LNCaP and from non‑cancerous RWPE‑1 cells according to
the Current Protocols in Cell Biology (John Wiley & Sons,
Inc.) using ultracentrifugation in an Optima XE‑90 ultracentrifuge (Beckman Coulter). Cells grown to 80% confluency
in complete growth medium were washed twice in medium
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Figure 1. Representative consecutive sections of normal (disease‑free) and cancerous (stage II, Gleason score of 5) human prostate tissues from a human tissue
microarray utilized in quantitative immunofluorescence. The sections are approximately 5 µm apart from each other, which allows to analyze near‑identical
areas for the expression of different markers (CD9, EGR‑1 and FASN), indicated by the dashed circles. Images were acquired by phase contrast light microscopy. EGR‑1, early growth response 1; FASN, fatty acid synthase.

without serum, then incubated at 37˚C for 48 h in medium
containing 10% exosome‑free FBS. Exosome‑free FBS was
prepared by a 2‑h long ultracentrifugation of medium/20% FBS
at 100,000 x g at 4˚C to pellet exosomes stemming from the
FBS. Upon collection of the medium from the cells, it was
subjected to the following sequential centrifugation procedure
(all steps at 4˚C): i) 300 x g for 10 min to remove live cells;
ii) 2,000 x g for 10 min to remove dead cells; iii) 10,000 x g for
30 min to remove cell debris; iv) 100,000 x g for 2 h to pellet
the exosomes; v) the resulting pellet was washed in phosphate
buffered saline (PBS) to remove contaminating proteins and
recentrifuged at 100,000 x g for 2 h to obtain exosomes of high
purity; vi) the final pellet was resuspended in a small volume
of PBS, typically 150 µl for an original of 40 ml culture
supernatant. Exosomes were aliquoted and stored short‑term
at ‑80˚C with avoidance of multiple freeze‑thaw cycles. The
amount and viability of cells giving rise to the exosomes was
determined by trypan blue exclusion assay and the cells were
frozen at ‑80˚C for western blot analysis (please see below).
The morphology of the isolated exosomes was further
characterized by atomic force microscopy using an MFP‑3D
origin atomic force microscope (AFM; Asylum Research). A
25 µl aliquot was dropped on amine‑functionalized (3‑aminopropyl) trimethoxysilane (APTMS) glass cover slips and dried
in air. The cover slips were washed by sonication with water,
acetone, ethanol and isopropyl alcohol before re‑soaked in an
ethanol solution of APTMS for 2 h. Conical‑shaped silicon
AFM probes with Al reflex coating (k=42 N/m) were mounted
on the cantilever holder and operated in AC mode. AFM
data were processed using MFP3D software written in an
IgorPro environment (Wavemetrics). Exosome dimensions on

the digitized images were quantified using ImageJ software
(https://imagej.nih.gov/ij/).
Treatment of cells with exosomes. RWPE‑1 cells were seeded in
6‑well plates at a density of 0.5x106 cells per well and incubated
at 37˚C for settlement and growth for 24 h. Either 5 or 50 µg
of LNCaP or 50 µg RWPE‑1 exosomes (as a negative control),
corresponded to 1.5x10 6 and 15.0x10 6 exosome‑producing
cells, respectively. The cells were incubated at 37˚C for 24 h,
washed twice in PBS following the removal of the supernatant,
and collected by either scraping or trypsinization followed by
mild centrifugation at 2,600 x g for 10 min at 4˚C. Cell pellets
were snap‑frozen in liquid nitrogen to preserve RNA and
protein integrity and were stored short term at ‑80˚C. Scraped
and trypsinized cells were used for analysis by western blot
analysis and reverse transcription‑quantitative polymerase
chain reaction (RT‑qPCR), respectively (please see below).
Western blot analysis. Western blot analysis was performed on
both the cultured cells and the exosomes derived therefrom.
Protein lysates were generated on ice in lysis buffer: 25 mM
Tris, 8 mM MgCl2, 1 mM DTT, 15% glycerol, 1% Triton X‑100
and protease inhibitor cocktail (Sigma). Insoluble material
was removed by centrifugation of the lysates at 20,000 x g
for 10 min at 4˚C. The protein concentration was determined
by Bradford assay (Sigma) against a bovine serum albumin
(BSA) standard. In total, 80 µg (for cell lysates) or 20 µg
(for exosomal lysates) total protein were size‑separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS‑PAGE) and electro‑transferred onto polyvinylidene
(PVDF) membranes. The membranes were stained with
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Figure 2. Immunostaining with control IgG (for background/absent staining),
anti‑CD9, anti‑EGR‑1 and anti‑FASN antibodies in human non‑cancerous
RWPE‑1 (A‑D) and cancerous LNCaP (E‑H) prostate cells. Images illustrate
fluorescence detected with Alexa Fluor 594 (red; excitation at 590 nm, emission at 618 nm). The smaller insets illustrate the same image (size reduced)
and stained with nuclear DAPI (blue) for single cell identification. Scale bars
(white bars) in all images represent 10 µm. EGR‑1, early growth response 1;
FASN, fatty acid synthase.

Figure 3. Representative detection of CD9, EGR‑1 and FASN by immunofluorescence in disease‑free (DF; A, D and G), tumor‑adjacent (ADJ;
B, E and H), and tumor (TUM; C, F and I) human prostate tissues. Images
illustrate fluorescence detected with Alexa Fluor 594 (red; excitation at
590 nm, emission at 618 nm). The smaller insets illustrate the same image
(size reduced) and stained with nuclear DAPI (blue) for single cell identification. Scale bars (white bars) in all images represent 10 µm. EGR‑1, early
growth response 1; FASN, fatty acid synthase.

0.1% Ponceau S [3‑hydroxy‑4‑(2‑sulfo‑4‑[4‑sulfophenylazo]
phenylazo)‑2,7‑naphthalenedisulfonic acid; Sigma] in
5% acetic acid for 5 min at room temperature to visualize
the blotted proteins. Following 2 brief washes in TBS, the
membranes were blocked with 5% milk powder in TBS
containing 0.05% Tween‑20 (TBST) and probed overnight
at 4˚C with the anti‑CD9, anti‑EGR‑1 and anti‑FASN antibodies listed above in the ‘Immunofluorescence’ paragraph,
and with anti‑androgen receptor (AR) antibody (sc‑816; AR
(N‑20), Santa Cruz Biotechnology), and with anti‑ β ‑actin
antibody (A1978, Sigma) (for cell extracts) and anti‑actin
antibody (A3853, Sigma) (for exosomes extracts) at typical
concentrations of 0.2 µg/ml in TBST. The detection and
chemiluminescent visualization (Clarity ECL Substrate,
Bio‑Rad) of target proteins was performed using secondary
horseradish peroxidase‑conjugated goat anti‑mouse (A0168;
Sigma) and goat anti‑rabbit (A0546; Sigma) antibodies used
at 1:15,000 dilutions for 1 h at room temperature. Band intensity (expression level) was quantified by densitometry using
ImageJ software (https://imagej.nih.gov/ij/).

using 100 ng of template cDNA and a final primer concentration of 900 nM. The cycling parameters were 95˚C for 5 min
followed by 45 cycles of 94˚C for 15 sec and 60˚C for 1 min.
Primers were designed using Primer Express software
(Invitrogen; Thermo Fisher Scientific) and synthesized by
Integrated DNA Technologies. The following primer sequences
(5' to 3') were used: EGR‑1 forward, GAGCAGCCCTAC
GAGCAC and reverse, AGCGGCCAGTATAGGTGATG;
FASN forward, AGAACTTGCAGGAGTTCTGGGACA and
reverse, TCCGAAGAAGGAGGCATCAAACCT; TATA
binding protein (TBP) forward, CACGAACCACGGCAC
TGATT and TBP reverse, TTTTCTTGCTGCCAGTCTGGAC.
RT‑qPCR reactions were performed in triplicate. Relative
expression levels were determined by the ΔΔCq method (22)
using TBP as the normalization control after determining that
amplification efficiencies were similar to the ones of the
control transcripts.

RT‑qPCR. RNA was isolated using spin column chromatography (Qiagen). In total, 1‑3 µg of RNA was transcribed into
cDNA using random decamers of the Retroscript RT kit (Life
Technologies; Thermo Fisher Scientific). mRNA expression
was quantitated in a CFX Connect Real Time PCR Detection
System from Bio‑Rad using the SYBR‑Green PCR Master
Mix and SYBR‑Green RT‑PCR Reagents kit (Life
Technologies; Thermo Fisher Scientific) in 25 µl reactions,

Statistical analysis. CD9, EGR‑1 and FASN expression levels
are represented by signal intensities (sum pixel count per
area) generated by quantitative immunofluorescence analysis
(as described above). Simple, yet straightforward statistical
methods were applied to the datasets using the Microsoft
Office Excel software package. Due to our previously observed
and well‑known intra‑ and inter‑specimen heterogeneity in
tissue expression studies (7,10,11), the datasets were inclusive,
i.e., all available informative images were utilized, and no
computational calculation was used to identify potential
outliers. The infinite variance due to tissue heterogeneity is
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expressed as the coefficient of variation in % in the text of the
‘Results’ section. Single factor analysis of variance (ANOVA)
was used to compare multiple datasets with unequal variances.
The post hoc Fishers' least significant difference (LSD) test
was used to determine the significance of the difference
between the means of the datasets. ANOVA followed by LSD
was also used to analyze the results of western blot analysis
and RT‑qPCR. Statistical significance in these comparisons of
the means was defined as P≤0.05. The datasets were mined for
potential associations between CD9 and EGR‑1 and between
CD9 and FASN by determining the Pearson's correlation
coefficient r. The significance for these observations was
determined by first calculating the t‑value of the correlation
using the equation t=r/SQRT(1‑r 2 /n‑2), where ‘r’ is the
correlation coefficient, ‘n’ is the number of samples, and ‘2’ is
the degree of freedom. The t‑value was then used to determine
the significance of ‘r’ by the two‑tailed Student t‑distribution
(TDIST; statistical significance defined as P≤0.05).
Results
Detection of CD9, EGR‑1 and FASN expression in human
prostate cells and tissues. The antibodies used to detect CD9,
EGR‑1 and FASN by immunofluorescence in human tissues
were first tested in the human non‑cancerous RWPE‑1 and in
the cancerous LNCaP cell models, which allowed the illustration of the specificity of the antibodies. As shown in Fig. 2,
CD9 staining was primarily evident for the cell surface, while
staining for FASN was primarily cytoplasmic for both cell
models, as expected. EGR‑1 staining seemed to be somewhat
more diffuse, in agreement with its reported possible localization in both the nucleus and the cytoplasm, depending on
cellular type and context (11,23). In addition, the expression
level for all three markers was slightly higher in the LNCaP
than in the RWPE‑1 cells. Important for the use of the antibodies in human tissues, the isotype‑matched unspecific
control antibody resulted in minimal, if any, staining in both
cell types.
The same antibodies and staining conditions were used to
detect CD9, EGR‑1 and FASN in human prostate tissues of
the cancerous type, histologically normal tumor‑adjacent, as
well as disease‑free specimens, as outlined in Table I. Due to
the higher complexity of human tissues compared to cultured
cells, the staining for all three protein markers was somewhat
more diffuse, but nevertheless typical for the corresponding
target, as shown in Fig. 3. A total of 336 digitized confocal
images from 22 individual specimens were used for the quantification of signal intensity (expression) by computational
detection of sum pixel count per area. The coefficients of
variation ranges for CD9, EGR‑1 and FASN expression were
14.5‑17.7, 16.1‑27.1 and 15.0‑21.3%, respectively (data not
shown). These are consistent with previous findings by the
authors (7,10,11) and generally indicate the well‑known intra‑
and inter‑tissue heterogeneity of expression. To acknowledge
this heterogeneity, an inclusive approach was adopted, i.e., any
computational determination of potential outliers was deemed
unjustified, and all available images of sufficient quality were
included for the analysis of expression. Group comparisons
by ANOVA revealed significant differences between the
types of tissues for all three markers (P<0.01). As shown in

Figure 4. Relative expression of (A) CD9, (B) EGR‑1, and (C) FASN in
disease‑free (DF), tumor‑adjacent (ADJ) and tumor (TUM) human prostate
tissues. The whisker plots/boxes represent group means (middle line) and
quartiles (25th and 75th percentiles) at their ends; lines above and below
boxes indicate the 10th and the 90th percentiles, respectively. The indicated
P‑values denote the level of statistical significance for the differences between
groups, as calculated by single factor ANOVA. *P≤0.05, significant difference in means compared to DF tissues; #P>0.05, no significant difference in
means between the ADJ and TUM groups. EGR‑1, early growth response 1;
FASN, fatty acid synthase.

Fig. 4A, CD9 mean expression was slightly, yet significantly
higher in tumor (1.1x) and in tumor‑adjacent (1.2x) compared
to disease‑free tissues (P<0.01), while it was similar between
tumor and tumor‑adjacent tissues (P>0.05). Similarly, as
shown in Fig. 4B, EGR‑1 mean expression in tumor (1.3x) and
tumor‑adjacent (1.5x) tissues was slightly, yet significantly
elevated compared to disease‑free tissues (P<0.01), while it was
similar between tumor and tumor‑adjacent tissues (P>0.05).
Finally, the same mean expression pattern was observed for
FASN (Fig. 4C), with expression levels in tumor (1.2x) and
tumor‑adjacent (1.1x) being slightly, yet significantly higher
than in disease‑free tissues (P<0.01) and similar between
tumor and tumor‑adjacent tissues (P>0.05). Taken together,
these results corroborate the field cancerized nature of tissues
adjacent to prostate adenocarcinomas.
Correlation between CD9, EGR‑1 and FASN expression
in human prostate tissues. In a previous study, the authors
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tumor‑adjacent and tumor tissues, respectively (Fig. 5A‑C).
Pearson's correlations between CD9 and FASN were r= 0.57
(P<0.01), r=0.59 (P<0.01) and r=0.54 (P<0.01) in disease‑free,
tumor‑adjacent and tumor tissues, respectively (Fig. 5D‑F).
The strongest correlations between CD9 and EGR‑1, and
between CD9 and FASN were thus observed in tumor‑adjacent
tissues. Given the rather high level of heterogeneity, these
values were deemed to be markedly high. Since CD9 expression represents exosome formation and excretion (24‑26) and
EGR‑1 is a marker of field cancerization (7,11), these results
suggest a potential role of exosomes in the formation of field
cancerization.

Figure 5. Correlation analysis between CD9 and (A‑C) EGR‑1 and between
(D‑F) CD9 and FASN in disease‑free (DF), tumor‑adjacent (ADJ) and
tumor (TUM) human prostate tissues. The x‑ and y‑axes of the scatter plots
represent relative expression in units of fluorescence, as calculated by the
NIS‑Elements AR 4.30.02/64bit software. Each dot represents a measurement data point and the dotted line represents the best fit of correlation.
‘r’ denotes the Pearson's correlation. The P‑value denotes the significance
for the Pearson's correlation based on the t‑value of the correlation and the
two‑tailed Student t‑distribution. Statistical significance is defined as P≤0.05.
EGR‑1, early growth response 1; FASN, fatty acid synthase.

reported on the correlation between EGR‑1 and other field
cancerization markers, i.e., platelet‑derived growth factor A
(PDGF‑A), macrophage inhibitory cytokine 1 (MIC‑1) and
FASN (7), with the question in mind of whether EGR‑1, as a
master transcription factor, could be a regulator of the other
three factors. Similarly, one major objective of the present
study was to explore the possibility that exosomes are effectors
of field cancerization in prostate tissues. Thus, this study aimed
to determine a potential association between the occurrence
of CD9 and EGR‑1, and between CD9 and FASN within the
individual types of tissues analyzed in this study, and at determining whether such a correlation changes in these different
types of tissues. This was possible by generating images at the
same position on the TMAs that were consecutive sections
approximately 5 µm apart from each other, as shown in
Fig. 1. Correlations between CD9 and EGR‑1, and between
CD9 and FASN were determined by Pearson's correlation
analysis, which is by default amenable to both positive and
negative correlations. Of particular interest was to determine
whether possible correlations differ between different types
of tissues, i.e., disease‑free, tumor‑adjacent and tumor tissues.
Pearson's correlations between CD9 and EGR‑1 were r= 0.44
(P<0.05), r=0.73 (P<0.01) and r=0.17 (P=0.32) in disease‑free,

Effect of exosomes from cancerous cells on non‑cancerous
cells. The potential of exosomes derived from cancer cells to
induce the expression of field cancerization markers, such as
EGR‑1 and FASN in non‑cancerous cells was experimentally
examined using the non‑cancerous RWPE‑1 and the cancerous
LNCaP cell models. The golden standard method was used,
i.e., ultracentrifugation, to isolate exosomes from LNCaP and
RWPE‑1 cells and determined their protein concentration.
Consistently, it was calculated that 1 µg exosomal protein
was produced by approximately 300,000 cells under standard
growth conditions during 24 h of culture. Atomic force microscopic analysis of the LNCaP and RWPE‑1 exosomes (Fig. 6)
revealed horizontal and vertical dimensions of 74.6±26.2 and
78.0±28.4 nm for the LNCaP cells (Fig. 6A), and 89.6±31.4
and 93.6±34.0 nm for the RWPE‑1 cells (Fig. 6B), respectively.
This size is in agreement with that of numerous previous reports
on exosomes from cells of prostatic origin (17‑20). LNCaP
and RWPE‑1 exosomes were also analyzed biochemically
by western blot analysis, along with the corresponding cells
that secreted them (Fig. 7). Immunodetection using specific
antibodies revealed the presence of CD9 in both exosomes
and cells. In accordance with previously reported proteomic
profiles of exosomes secreted by prostate cells (24), actin and
FASN were also detected in both LNCaP cells and exosomes,
although FASN expression was under the detection limit for
RWPE‑1 cells. However, another study did not report the presence of FASN in LNCaP exosomes, but instead reported the
presence of AR (26), which we did not find in either cell types.
These discrepancies may be due to different culture conditions,
collection times, and other experimental and/or analytical
parameters. EGR‑1 was detected in the cellular extracts,
but not in the exosomal lysates, which is congruent with its
absence in the previously reported proteomic profiles (24,26).
Finally, the AR was expressed in LNCaP cells, but was virtually absent in RWPE‑1 cells if not induced by excess androgen
as reported (ATCC) (Fig. 7).
To examine the effect of prostate cancer cell‑derived
exosomes on the expression of the two field cancerization
markers EGR‑1 and FASN in non‑cancerous prostate cells, the
RWPE‑1 cells were treated with LNCaP‑derived exosomes at
a 3:1 and 30:1 cell‑to‑cell ratio for 16 h. The protein profiles
of the lysates of the treated RWPE‑1 cells did not appear to
be different from the control, suggesting that the exosomes
did not induce major expressional changes (data not shown).
Western blot analysis revealed an inducive effect of up to
3.5‑fold, for EGR‑1, but only up to 1.5‑fold for FASN (Fig. 8).
FASN protein has previously been demonstrated to be part
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Figure 6. Characterization of cancerous (A) LNCaP and non‑cancerous (B) RWPE‑1 prostate cell‑derived exosomes. The left panels illustrate the atomic force
microscopic image of exosomes. The distances (in μm) are indicated on the x‑ and y‑axes. The grey scale bars on the right indicate the height of the particles.
The right panels illustrate the horizontal and vertical size distribution (in nm) of the particles. The whisker plots/boxes represent group means (middle line)
and quartiles (25th and 75th percentiles) at their ends; lines above and below boxes indicate the 10th and the 90th percentiles, respectively. EGR‑1, early growth
response 1; FASN, fatty acid synthase.

Figure 7. Detection of CD9, FASN, AR, EGR‑1 and actin in LNCaP and RWPE‑1 cells (represented by ‘C’) and exosomes (represented by ‘E’) by western blot
analysis/chemiluminescence. The standard marker and the protein profiles are stained with Ponceau S dye. EGR‑1, early growth response 1; FASN, fatty acid
synthase.

of the exosomal content released by prostate cells (24). Thus,
in order to demonstrate that a possible inducive expression
was due to transcriptional activation, the induction of FASN
mRNA was measured by RT‑qPCR. At lower concentrations of exosomes, FASN mRNA transcription was induced
approximately 10‑fold. Similarly, EGR‑1 mRNA was induced
approximately 8‑fold (Fig. 9). Overall, these results are in
good agreement with the observations made in the tissues and

suggest a regulatory association between exosome release and
FASN and EGR‑1 expression in human prostate tissues.
Discussion
Several reviews of molecular pathology known as field cancerization, or the field effect, have emphasized its potential to
improve the clinical management of solid tumors, including

INTERNATIONAL JOURNAL OF ONCOLOGY 56: 957-968, 2020

965

Figure 8. Effect of LNCaP prostate cancer cell‑derived exosomes (5 or 50 µg) on non‑cancerous RWPE‑1 prostate cells. The top panel illustrates relative
protein expression of FASN and EGR‑1 in RWPE‑1 cells treated with LNCaP‑derived exosomes (Exo) or with 50 µg exosomes from non‑cancerous RWPE‑1
cells (control). β‑actin was used as a protein loading control. The bottom panel illustrates the quantification of chemiluminescent detection of FASN and EGR‑1
by densitometry (ImageJ software). Bars show the average of 3 independent experiments [± standard error (SE)] and represent the ratio of FASN and EGR‑1
with β‑actin signal (control) set to 1.0 and FASN and EGR‑1 compared to RWPE‑1 exosome control. *P≤0.05, statistical significance compared to the control.
EGR‑1, early growth response 1; FASN, fatty acid synthase.

prostate cancer (6,13,14,27). In this regard, it is conceivable that
the molecular aberrations, be it of genetic, epigenetic and/or
biochemical nature, could act as biomarkers along the entire
development of the disease and/or as molecular targets for
preventative or interventive therapy. The authors have previously contributed to the identification of markers of prostate
field cancerization and have reported on their potential clinical
uses, thereby validating some of them (7‑13). Accordingly, the
authors have previously reported on two recurrent markers of
field cancerization, i.e., the key transcription factor and master
regulator, EGR‑1, and the lipogenic enzyme, FASN, specifically their upregulation at the protein level in histologically
normal tissue adjacent to prostate tumors when compared to
disease‑free, truly normal prostatic tissues (7,8,11). It is not
inconceivable that such molecular aberrations could be used
for example, to improve the diagnosis of prostate cancer in
false‑negative biopsies (13). The latter continue to challenge
confirmatory diagnoses of prostate adenocarcinoma following
an abnormal prostate‑specific antigen (PSA) test or suspicious
digital rectal examination (DRE) (28‑31). In this scenario,
tissue affected by field cancerization increases the clinically
informative area under microscopic analysis by the surgical
pathologist when combined with immunological techniques.
This could lead to a reduction of repeat biopsies and thus, a
more effective clinical management. The possibility to predict
the existence of lesions in a tissue without their visual detection
has prompted others to call tissues affected by field cancerization ‘TINT’, for ‘tumor indicating normal tissue’ (32). Even
in the case of a positive detection of cancerous tissue in biopsies, markers of field cancerization could have a meaningful
application. The clinical setting referred to here is active
surveillance, which is increasingly chosen by patients diagnosed with low‑risk prostate cancer, defined as low number

Figure 9. Effect of LNCaP prostate cancer cell‑derived exosomes on
non‑cancerous RWPE‑1 prostate cells. Relative mRNA expression of FASN
and EGR‑1 in RWPE‑1 cells treated with LNCaP‑derived or RWPE‑1‑derived
exosomes (control). Bars show the average of 3 independent experiments
[± standard error (SE)]. Control is set to 1.0 and FASN and EGR‑1 are compared to the control. *P≤0.05, statistical significance compared to the control.
EGR‑1, early growth response 1; FASN, fatty acid synthase.

of positive biopsy cores, low % of tissue affected and low
Gleason grade (33, 34). Active surveillance programs are
meant to defer more aggressive treatments of curative intent
but with quality of life lowering side effects, including radical
prostatectomy (35,36). These programs include frequent PSA
testing and the histological examination of repeat biopsies
to monitor potential cancer progression. It is thus conceivable that well‑defined areas, markers and parameters of field
cancerization could be monitored during this time. Similarly,
the effect of neoadjuvant therapeutic interventions could be
assessed during this pre‑surgical setting (13,37). The extent
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of field cancerization could also be indicative of a positive
surgical margin, which is an important clinical parameter in
the administration of focal therapy, a less invasive therapeutic
modality on the rise (13,38). In this scenario, the presence of a
field effect at the margin may be indicative of an elevated risk
for progression or of the extent of tumor multifocality within
the prostate (39). Lastly, given the widely accepted premise
that the observed molecular aberrations in histologically
normal tissues constitute a state of pre‑malignancy, markers
of field cancerization could represent targets for therapeutic
intervention (13,32).
Regardless of the potential clinical application, it
is widely accepted that the molecular etiology of field
cancerization should be understood in order to fully benefit
from it. It is thus important to identify the distinct cellular
and molecular mechanisms and pathways that result in the
molecular aberrations observed in tissues affected by a field
effect. For example, for the afore‑mentioned protein factors
EGR‑1 and FASN, the events that lead to their upregulation
in histologically normal tissues adjacent to existing prostate
tumors remain unknown. Thus, it would be of interest to
determine the mechanisms through which a prostate tumor
lesion influences its surrounding tissues, thereby potentially
priming it for the induction of multifocal disease. As is
well‑known from 2019, the role of exosomes in cell‑to‑cell
and in tissue‑to‑tissue communication has been established
and proven to be a major mode of physiological and
reciprocal interactions in multicellular organisms (15,16).
While studies of exosomes of prostatic origin tend to focus
on their application as biomarkers in liquid biopsy schemes
and on the molecular characterization of their content (17‑20),
reports on specific exosomal factors on the genotype and
phenotype of recipient cells are now increasing in number.
For example, prostate cancer cell‑derived exosomes have
been shown to inhibit and promote osteoclast and osteoblast
cell activity, respectively (40,41), which could promote the
overall osteoblastic phenotype of prostate cancer metastases.
Exosomes shed by prostate cancer cells have been shown
to carry integrin αvβ3 which, when deposited in recipient
cells, is postulated to increase their motility (42). Similarly,
the motility of stromal cells has been shown to increase by
prostate cancer exosomes (43). Hypoxia‑induced exosomes
lead to increased prostate cell survival and invasiveness by
targeting molecules of the adherens junctions (44,45), while
the exosomal factor and tetraspanin CD9 promotes prostate
cancer cell growth under androgen‑deprived conditions (46).
Based on such reports, the existence of a new link has been
hypothesized between cancer cell‑derived exosomes and the
induction of field cancerization. Accordingly, the present
study attempted for the first time, at least to the best of our
knowledge, to demonstrate a quantitative association between
the exosomal marker, CD9, and our previously identified
markers of field effect, EGR‑1 and FASN. This study on a
pilot tissue cohort indicates a positive correlation between
CD9 expression on one side and EGR‑1 and FASN expression
on the other, with the link with the former factor being more
significant. The authors have previously demonstrated that
these two factors are upregulated in prostate tissues resected
1 cm from the visible tumor margin at both the mRNA
and protein level (7,8,11). The induction of both factors in

histologically normal areas of the prostate by tumor‑derived
exosomes is congruent with our hypothesis of a ‘priming’,
potentially tumor‑promoting effect. EGR‑1 is a central
transcription regulator of a number of molecular pathways
and acts divergently according to the cell context (23,47,48).
However, in prostate tumors it acts as a promoter of cancer
progression (47,49,50). FASN is equally established in
prostate cancer and has been termed a metabolic oncogene. It
promotes tumor cell proliferation through lipid biosynthesis
and the post‑translational modification of proteins and is
the focus of ongoing efforts to develop specific inhibitors
of its enzymatic activity (51, 52). Of note, the authors have
previously demonstrated a potential regulatory function of
EGR‑1 for FASN expression (7). Overall, the data presented
in this report corroborates in an independent tissue cohort
and data set that EGR‑1 and FASN are recurrent markers
of prostate field cancerization. Of note, the magnitude of
the overexpression of EGR‑1 and FASN in field cancerized
prostate tissues can vary in independent studies due to tissue
heterogeneity and to the type of antibodies used. Of note
however, the present study independently corroborates the
previous findings by the authors (7,10,11). In addition, for both
factors, future studies are required to include testing whether
their transcriptional and enzymatic activities, respectively,
are also heightened in field cancerized tissues. As a novel
observation, the data of the present study demonstrate that
CD9 expression contributes similarly to this phenomenon
through its change (increase) from disease‑free to
tumor‑adjacent and to histologically cancerous tissues. The
authors acknowledge the possibility that the observed CD9
staining in the tissues can be due to its documented expression
in prostate gland epithelial cells (proteinatlas.org). Since CD9
is also a proven exosomal marker (24), it is not inconceivable
that the observed expression is representative of exosomal
release. However, the findings of this study need to be
corroborated in follow‑up studies using additional exosomal
markers, including for example CD63 (53). Importantly,
the results of this study support the notion that exosomes
released by cancerous lesions in the prostate could induce
the upregulation of factors that promote the biochemical
transformation of physiologically and phenotypically normal
cells, leading to the formation of molecularly altered fields.
For EGR‑1, the data of this study are congruent with those
of other studies in other cell systems, where exosomes exert
their actions through EGR‑1 expression and activation, for
example in muscle cells affected by exosomes released by
adipose cells (54).
For the most part, in this study, the in vitro data using the
LNCaP and the RWPE‑1 cell models support the associations
made in situ in human tissues, although the link between CD9
(exosomes) and EGR‑1 (field effect) is clearer. With respect
to FASN, this study prompts for caution when comparing
observations made in tissues with those made in cell models.
This is due to the fact that FASN may be part of the ‘cargo’
of exosomes released by prostate cancer cells, although
conflicting results exist (24,26). Of note, the results of this
study support the those of the study by Duijvesz et al (24).
Thus, an elevated FASN expression in field cancerization may
be, at least in part, directly due to exosomal FASN delivery.
The in vitro experiments of this study, however, indicate de
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novo induction of FASN mRNA, which, for the most part,
is accompanied by corresponding protein levels. The FASN
experiments performed herein warrant further investigations using functional approaches in systems that reflect the
complexity of human tissues. The same may be true for the
AR, the presence of which in prostate exosomes is equally
inconclusive (24,26). It is known that in cultured cells, the
physiological complexity is relatively low and may not reflect
entirely the complex regulatory networks at work in tissues.
With respect to the latter, it can be argued that tissue studies
are static and compromised by sample heterogeneity. However,
they are also physiologically relevant and better reflect the
complexity of cellular and molecular pathways influenced by
the environment, for example in animal models. Importantly,
it is demonstrated herein that when coupled with sophisticated
and quantitative data acquisition methods, they can deliver
meaningful indications of molecular associations in a physiologically relevant in situ environment, even in the presence
of high heterogeneity. As it is widely accepted that field effect
represents a pre‑malignant state, such knowledge may aid in
the development of targeted intervention strategies preventing
progression of pre‑malignancy to cancer.
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